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Misfolded or improperly assembled proteins in the endoplasmic reticulum (ER) are exported into the cytosol and
degraded via the ubiquitin–proteasome pathway, a process termed ER-associated degradation (ERAD). Saccharomyces
cerevisiae Hrd1p/Der3p is an ER membrane-spanning ubiquitin ligase that participates in ERAD of the cystic fibrosis
transmembrane conductance regulator (CFTR) when CFTR is exogenously expressed in yeast cells. Two mammalian
orthologues of yeast Hrd1p/Der3p, gp78 and HRD1, have been reported. Here, we demonstrate that gp78, but not HRD1,
participates in ERAD of the CFTR mutant CFTRF508, by specifically promoting ubiquitylation of CFTRF508. Domain
swapping experiments and deletion analysis revealed that gp78 binds to CFTRF508 through its ubiquitin binding
region, the so-called coupling of ubiquitin to ER degradation (CUE) domain. Gp78 polyubiquitylated in vitro an
N-terminal ubiquitin-glutathione-S-transferase (GST)-fusion protein, but not GST alone. This suggests that gp78 recog-
nizes the ubiquitin that is already conjugated to CFTRF508 and catalyzes further polyubiquitylation of CFTRF508 in
a manner similar to that of a multiubiquitin chain assembly factor (E4). Furthermore, we revealed by small interfering
RNA methods that the ubiquitin ligase RMA1 functioned as an E3 enzyme upstream of gp78. Our data demonstrates that
gp78 cooperates with RMA1 with E4-like activity in the ERAD of CFTRF508.
INTRODUCTION
In the eukaryotic cell secretory pathway, a significant pro-
portion of proteins that enter the endoplasmic reticulum
(ER) are specifically extracted from the ER and targeted to
the cytosol, where they are degraded by the ubiquitin–
proteasome system in a process known as ER-associated
degradation (ERAD) (Meusser et al., 2005). Whereas mis-
folded, improperly assembled, and metabolically regulated
endogenous proteins are targeted by the ERAD machinery
as an ER quality control system, in some cases the machinery
is usurped by exogenous factors, such as viruses and bacte-
rial toxins (Meusser et al., 2005). In ERAD, protein ubiquity-
lation plays a role in both protein extraction from the ER and
proteasomal protein degradation. This crucial protein mod-
ification is mediated by a set of three enzymes: a ubiquitin-
activating enzyme (E1), a ubiquitin-conjugating enzyme
(E2), and a ubiquitin ligase (E3) (Hershko et al., 2000). In
some cases, a multiubiquitin chain assembly factor (E4) is
also involved (Koegl et al., 1999; Hoppe, 2005). Although the
precise mechanism has not been clarified, the E4 protein acts
to promote multiubiquitylation of mono- or oligoubiquity-
lated substrates. Ufd2p, an E4 enzyme, is implicated in yeast
ERAD, but it is not known whether E4 enzymes play a role
in ERAD in mammals (Hoppe, 2005; Richly et al., 2005).
Cystic fibrosis transmembrane conductance regulator
(CFTR) is a cell surface chloride ion channel. A large portion
of CFTR is degraded by the ERAD machinery due to ineffi-
cient folding (Kopito, 1999). Several mutations in CFTR are
associated with the severe genetic disorder cystic fibrosis
(CF), but the majority of CF patients carry the F508 muta-
tion (Kopito, 1999). The ubiquitin ligases CHIP, Fbs1, and
RMA1/RNF5 have been implicated in the clearance of CFTR
in mammalian cells (Meacham et al., 2001; Yoshida et al.,
2002; Younger et al., 2006). Genetic analysis has suggested
that another ubiquitin ligase, Hrd1p/Der3p, is also involved
in ERAD of CFTR (Gnann et al., 2004).
Saccharomyces cerevisiae Hrd1p is an integral membrane
ubiquitin ligase that contains a RING finger domain facing
the cytosol, which functions predominantly with the E2
This article was published online ahead of print in MBC in Press
(http://www.molbiolcell.org/cgi/doi/10.1091/mbc.E07–06–0601)
on January 23, 2008.
Address correspondence to: Kazuhiro Nagata (nagata@frontier.
kyoto-u.ac.jp).
Abbreviations used: CFTR, cystic fibrosis transmembrane conduc-
tance regulator; CUE, coupling of ubiquitin to ER degradation; ER,
endoplasmic reticulum; ERAD, endoplasmic reticulum-associated
degradation; GFP, green fluorescent protein; HA, hemagglutinin;
siRNA, small interfering RNA.
1328 © 2008 by The American Society for Cell Biology
enzyme Ubc7p in the ERAD pathway (Hampton et al., 1996;
Bordallo et al., 1998; Bays et al., 2001; Deak and Wolf, 2001).
Although there is no CFTR orthologue in yeast, Hrd1p is
involved in the ERAD of human CFTR when it is exog-
enously expressed in yeast cells (Gnann et al., 2004).
There are two mammalian proteins that are structurally
and functionally related to yeast Hrd1p, gp78/autocrine
motility factor receptor and HRD1/Synoviolin (Fang et al.,
2001; Amano et al., 2003; Kikkert et al., 2004). Gp78 was
originally identified as a 78-kDa cell surface receptor for a
tumor cell autocrine motility factor that promotes tumor
metastasis (Nabi and Raz, 1987). Subsequently, it was shown
that gp78 localizes not only to the cell surface but also to the
ER (Wang et al., 1997). Similar to Hrd1p, gp78 is a RING
finger-dependent ubiquitin ligase, an integral ER membrane
protein, and it is involved in ERAD, in cooperation with
Ube2g2/UBC7, the mammalian counterpart of yeast Ubc7p
(Fang et al., 2001; Liang et al., 2003; Song et al., 2005; Lee et al.,
2006). Recently, Chen et al. (2006) demonstrated that both the
E2 binding site and the coupling of ubiquitin to ER degra-
dation (CUE) domain of gp78 are essential for its ubiquitin
ligase activity. Although recent biochemical and structural
studies have helped define the ubiquitin binding properties
of CUE domains (Ponting, 2000; Kang et al., 2003; Prag et al.,
2003), the role of the gp78 CUE domain in ubiquitin ligation
remains unclear. HRD1 is also a RING finger-dependent
ubiquitin ligase, located in the ER, and it is involved in
ERAD, in cooperation with Ube2g2 (Kaneko et al., 2002;
Nadav et al., 2003; Kikkert et al., 2004).
Although Hrd1p is involved in the ERAD of exogenously
expressed human CFTR in yeast cells, it is not known
whether its mammalian counterparts are involved in the
ERAD of CFTR in mammalian cells. Here, we demonstrate
that gp78, but not HRD1, is involved in the ERAD of a
mutant form of CFTR in mammalian cells, and that this
activity is dependent on the CUE domain of gp78. We also
show that the gp78 CUE domain confers an E4-like ubiquitin
ligase activity to gp78, which catalyzes multiubiquitin chain
assembly on CFTRF508 after initial ubiquitylation by
RMA1 in vivo.
MATERIALS AND METHODS
Plasmids, Antibodies, and Small Interfering RNA (siRNA)
Duplexes
The open reading frame (ORF) of mouse gp78 (BC040338) was cloned as
follows: a 5 1038-base pair fragment was amplified from a mouse embryonic
day 15.5 cDNA library (Invitrogen, Carlsbad, CA) by polymerase chain reac-
tion (PCR), and inserted into pT7Blue (Clonetech, Mountain View, CA). A 3
1381-base pair fragment that included the 3 untranslated region was isolated
from a mouse liver cDNA library (Marathon cDNA library; Clonetech) by
rapid amplification of cDNA ends, and inserted into pT7Blue. The full-length
ORF of gp78 was generated by fusing the two fragments together at the SalI
site in the region of overlap of the two fragments. The full-length gp78 ORF
was inserted into pcDNA3.1 () (Invitrogen), then it was subcloned into
pcDNA3.1/Myc-His()A (Invitrogen) to generate gp78-Myc. The cDNA for
mouse HRD1 (NM_028769) was amplified from a mouse embryonic day 17
cDNA library (MATCHMAKER cDNA library; Clonetech), and then it was
inserted into pcDNA3.1/Myc-His()A to generate HRD1-Myc. The single
point mutations in the RING domains of gp78 and HRD1, C337/374S (for Rfm
gp78-Myc) and C329S (for Rfm HRD1-Myc), respectively, were generated by
using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla,
CA). The point mutations in the CUE domain of gp78, MFP463/464/465AAR,
were generated by using the same kit.
To generate wild-type and Rfm GGH-Myc, a 5 1479-base pair fragment of
wild-type or Rfm gp78 with a BamHI site at its 3 end, and a 3 438-base pair
fragment of HRD1 carrying a BamHI site at its 5 end were amplified by PCR,
fused at the BamHI site, and introduced into pcDNA3.1/Myc-His()A. Gly-
cine and serine residues corresponding to the additional BamHI site were
subsequently inserted into the joint of the chimeric protein. GHH-Myc and
Rfm GHH-Myc were obtained by fusing a 5 927-base pair fragment of gp78
and a 3 1047-base pair fragment of wild-type or Rfm HRD1. HHG-Myc and
Rfm HHG-Myc were generated by fusing a 5 1338-base pair fragment of
wild-type or Rfm HRD1 with a 3 438-base pair fragment of gp78. HGG-Myc
and Rfm HGG-Myc were generated by fusing a 5 789-base pair fragment of
mHRD1 and a 3 993-base pair fragment of wild-type or Rfm gp78. Glycine
and serine residues corresponding to the insertional BamHI site were incor-
porated into all chimeric proteins. GXG-Myc was obtained by fusing a 5
927-base pair fragment and a 3 438-base pair fragment of gp78, which carried
the glycine and serine residues of the BamHI site. The CUE domain deletion
of gp78-Myc was generated by fusing a 5 1323-base pair fragment and a 3
438-base pair fragment of gp78, which carried the glycine and serine residues
of the BamHI site. The CUE domain insertion of HRD1-Myc was generated by
fusing a 5 1194 base pair fragment of HRD1 carrying a HindIII site at its 3
end with a 3 648 base pair fragment of GGH-Myc carrying a HindIII site at
its 5 end. Lysine and leucine residues of the HindIII site were incorporated
into the CUE domain insertional mutant HRD1-Myc, in addition to the
glycine and serine residues of the insertion site of GGH-Myc.
To generate GST-gp78, a 3 993-base pair fragment of gp78 was subcloned
into pGEX5X-1 (GE Healthcare Bio-Sciences, Little Chalfont, Buckingham-
shire, United Kingdom). The same region, but lacking the CUE domain, was
subcloned into the same vector to generate GST-CUE. To generate GST-
HRD1, a 1047-base pair fragment of HRD1 was subcloned into pGEX5X-1.
The expression vector for hemagglutinin (HA)-ubiquitin was described
previously (Sato et al., 2006). The expression vector for C-terminally Myc-
tagged Derlin1, -2, and -3 were described previously (Oda et al., 2006). The
expression vector for Flag-RMA1 was described in Younger et al. (2006). The
expression vector for CFTRF508-GFP was a kind gift from Dr. Ron R. Kopito
(Stanford University, Stanford, CA).
Mouse monoclonal anti-valosin containing protein (VCP) antibodies were
purchased from Affinity BioReagents (Golden, CO). Monoclonal anti-green
fluorescent protein (GFP) antibody and polyclonal anti-Myc antibodies used
for immunoblot analysis were purchased from Roche Diagnostics (Indianap-
olis, IN) and Santa Cruz Biotechnology (Santa Cruz, CA), respectively. Mono-
clonal anti-Myc antibody clone 9E10 and monoclonal anti-Flag antibody clone
M2 was purchased from Santa Cruz Biotechnology. Polyclonal anti-CHIP
antibody was purchased from Calbiochem (San Diego, CA), and monoclonal
anti-actin antibody was from Chemicon International (Temecula, CA).
siRNA duplexes targeting CHIP (HSS145537 and HSS145538) and gp78
(HSS100447 and HSS100449) were purchased from Invitrogen, and those for
RMA1 were from Dharmacon RNA Technologies (Lafayette, CO) and QIA-
GEN (Valencia, CA) (SI03157014). The negative control siRNA duplexes were
purchased from Dharmacon RNA Technologies.
Cell Culture and Transfection
Human embryonic kidney (HEK)293 cells were cultured in DMEM (Invitro-
gen) supplemented with 10% fetal bovine serum and antibiotics (100 U/ml
penicillin G and 100 U/ml streptomycin). Plasmids and siRNA duplexes were
transfected into cells by using FuGENE 6 transfection reagent (Roche Diag-
nostics) or Lipofectamine RNAiMAX (Invitrogen), respectively, according to
the manufacturer’s instructions.
In Vivo Ubiquitylation Assay
Cells were lysed in buffer containing 50 mM Tris-HCl, pH 8.0, 1% NP-40, and
150 mM NaCl, and then they were centrifuged at 13,000  g. The supernatants
were incubated with anti-GFP antibody (mouse monoclonal; Roche Diagnos-
tics), and immune complexes were captured using protein G-Sepharose (GE
Healthcare Bio-Sciences). Immunoprecipitates were subjected to immunoblot
analysis by using an anti HA-antibody (rabbit polyclonal; Santa Cruz Bio-
technology). Immunoreactive proteins were detected using Can Get Signal
(Toyobo Engineering, Osaka, Japan).
Metabolic Labeling and Immunoprecipitation
Cells were incubated for 30 min in methionine- and cysteine-free DMEM
supplemented with 2 mM glutamine and 10% dialyzed fetal bovine serum.
Cells were then pulsed with 4.1 Mbq/3.5-cm dish of EXPRESS labeling
mixture (PerkinElmer Life and Analytical Sciences, Boston, MA), and chased
with fresh complete medium. Cells were lysed in buffer containing 50 mM
Tris-HCl, pH 8.0, 1% NP-40, and 150 mM NaCl, and supernatants were
incubated with anti-GFP antibody (rabbit polyclonal or mouse monoclonal,
MBL International [Woburn, MA], or Roche, respectively). Immune com-
plexes were captured using protein A-Sepharose (GE Healthcare Bio-Sci-
ences). Beads were washed twice in the same buffer used to lyse the cells, and
then they were boiled in Laemmli sample buffer. Immunoprecipitates were
separated by SDS-polyacrylamide gel electrophoresis (PAGE), and radioac-
tivity of specific bands was quantified using a Storm PhosphorImager (GE
Healthcare Bio-Sciences).
In Vitro Ubiquitin Binding Assay
GST-fusion proteins expressed in Escherichia coli were captured on glutathione
(GSH)-Sepharose beads. Equal amounts of GST fusion proteins, as measured
by Coomassie Blue staining, and oligoubiquitin mixture were incubated in
buffer containing 50 mM Tris-HCl, pH 8.0, and 150 mM NaCl at 4°C for 1 h.
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GST-fusion proteins conjugated to GSH-Sepharose were collected by centrif-
ugation, and coprecipitating ubiquitin was analyzed by immunoblot using
anti-ubiquitin antibody (mouse monoclonal; Laboratories, South San Fran-
cisco, CA).
Protein Preparation for In Vitro Ubiquitylation Assay
Bovine ubiquitin was purchased from Sigma-Aldrich (St. Louis, MO). The
ORF of human Ube2g2 was amplified by reverse transcription-PCR. cDNAs
corresponding to Ube2g2 and ubiquitin-GST fusion protein (ub-GST) were
cloned into pT7–7. The ub-GST could only be a substrate but not a source of
ubiquitylation reaction in in vitro assay system, because GST was fused to the
C terminus of ubiquitin and thereby prevents ubiquitin activation by E1
enzyme. His6-E1 baculovirus and bacterial expression were performed as
described previously (Iwai et al., 1999). pGEX-2T was used for expression and
purification of GST from bacteria (GE Healthcare Bio-Sciences). Ubiquitin
ligases (gp78-Myc, gp78CUE-Myc, HRD1-Myc, HRD1CUE-Myc, and Flag-
RMA1) were obtained from respective ubiquitin ligase-overexpressing
HEK293 cells. The ubiquitin ligase-overexpressing cells were lysed in buffer
containing 50 mM Tris-HCl, pH 8.0, 1% NP-40, and 150 mM NaCl, and then
they were centrifuged at 13,000  g. Membrane-spanning ubiquitin ligases
were solubilized into supernatants with 1% NP-40. The supernatants were
incubated with 10 g of anti-Myc antibody (mouse monoclonal clone 9E10;
Santa Cruz Biotechnology) or 10 g of anti-Flag antibody (mouse monoclonal
clone M2; Santa Cruz Biotechnology), and immune complexes were captured
using 10 l of protein G-Sepharose (GE Healthcare Bio-Sciences).
In Vitro Ubiquitylation Assay
One microgram of GST or ub-GST was incubated for 2 h at 37°C in a reaction
volume of 20 l of Tris-HCl, pH 7.5, containing 5 g of ubiquitin, 100 ng of
E1, 200 ng of Ubc7, 5 mM MgCl2, 2 mM dithiothreitol, 0.5 mM ATP, 10 mM
creatine phosphate, 1 g of creatine phosphokinase, and ubiquitin ligase
immune complexes captured on 10 l of protein G-Sepharose (described
above). Reactions were terminated by the addition of 20 l of Laemmli sample
buffer, and proteins were separated by 10% SDS PAGE and visualized by
immunoblot using anti-GST antibody (mouse monoclonal; Santa Cruz Bio-
technology).
RESULTS
Gp78 Is Involved in ERAD of CFTRF508
To evaluate whether gp78 and HRD1 were involved in the
clearance of CFTR in mammalian cells, we examined the
effect of gp78 and HRD1 expression on polyubiquitylation of
the most common mutant form of CFTR, CFTRF508. Ex-
pression vectors for a CFTRF508 fused with GFP at the C
terminus (CFTRF508-GFP) and an ubiquitin fused with
HA at the N terminus (HA-ubiquitin) were transiently trans-
fected into HEK293 cells. Ubiquitylated CFTRF508-GFP
was detected by immunoprecipitation with anti-GFP anti-
body followed by immunoblot using anti-HA antibody. As
shown in Figure 1A, polyubiquitylation of CFTRF508-GFP
was enhanced by coexpression of a gp78 fused with Myc
epitope at the C terminus (gp78-Myc), but it was not affected
by coexpression of HRD1-Myc. Expression of a RING finger
mutant of gp78 (Rfm gp78-Myc), but not HRD1 (Rfm HRD1-
myc), exerted a dominant-negative effect that suppressed
polyubiquitylation of CFTRF508-GFP (Figure 1A). Similar
results were obtained when the immunoprecipitated pro-
teins were analyzed under denaturing conditions, which
indicated that the ubiquitylation we observed was not due
to nonspecific ubiquitylated proteins that coimmunopre-
cipitated with CFTRF508-GFP (Supplemental Figure 1).
Thus, gp78 specifically promoted polyubiquitylation of
CFTRF508.
Next, we examined whether gp78 physically interacted
with CFTRF508 in HEK293 cells. Immunoprecipitation
with anti-GFP antibody followed by immunoblot using
anti-Myc antibody revealed that gp78-Myc, but not
HRD1-Myc, physically interacted with CFTRF508-GFP
(Figure 1B). Similar binding was also observed for Rfm
gp78-Myc (data not shown). Notably, p97/VCP, which
cooperates with gp78 in ERAD (Zhong et al., 2004; Ballar
et al., 2006), coimmunoprecipitated with CFTRF508
when gp78-Myc was expressed in cells (Supplemental
Figure 2). These results indicated that gp78 associates
with CFTRF508 and that it recruits p97 to CFTRF508
complexes.
Ubiquitylation of CFTRF508 is followed by proteasomal
degradation. We examined the effect of gp78 on the degra-
dation of CFTRF508 by using a pulse-chase experiment.
Coexpression of Rfm gp78-Myc, but not Rfm HRD1-Myc,
exerted a dominant-negative effect that delayed the degra-
dation of CFTRF508-GFP (Figure 1, C and D). This was
consistent with the previous observation that gp78, but not
HRD1, physically associated with CFTRF508, and that Rfm
gp78, but not Rfm HRD1 markedly inhibited the ubiquity-
lation of CFTRF508. Thus, similar to yeast Hrd1p, gp78
seemed to be involved in the ERAD of CFTRF508 in mam-
malian cells. Coexpression of wild-type gp78-Myc had no
effect on the degradation of CFTRF508-GFP (Supplemental
Figure 3), even though it enhanced the ubiquitylation of
CFTRF508-GFP. Overexpression of gp78 has been shown
to accelerate the degradation of other gp78 substrates (Fang
et al., 2003; Song et al., 2005; Chen et al., 2006), which suggests
that additional factor(s) are required for the degradation of
CFTRF508.
Figure 1. Gp78 but not HRD1 is involved in the ERAD of
CFTRF508. (A) Gp78 promotes ubiquitylation of CFTRF508.
HEK293 cells transiently expressing CFTRF508-GFP and HA-ubiq-
uitin, with or without (control lane) the indicated ubiquitin ligases,
were lysed and subjected to immunoprecipitation by using anti-GFP
antibody, followed by immunoblot using anti-HA antibody. (B)
Gp78 physically interacts with CFTRF508. HEK293 cells tran-
siently expressing CFTRF508-GFP and the indicated ubiquitin li-
gases were lysed and subjected to immunoprecipitation by using
anti-GFP antibody, and immune complexes were analyzed by im-
munoblot using anti-Myc antibody. (C) Rfm gp78 delays ERAD of
CFTRF508. HEK293 cells transiently expressing CFTRF508-GFP,
together with Rfm gp78-Myc or Rfm HRD1-Myc, were pulse-la-
beled for 30 min with [35S]methionine, and after the indicated chase
period, CFTRF508-GFP was immunoprecipitated and analyzed by
autoradiography. (D) Quantitation of the data presented in C. Ra-
dioactivity of CFTRF508-GFP at each time point was normalized to
the value at chase time point 0 h. The data represents the averages
and SD of three independent experiments. IP, immunoprecipitation;
IB, immunoblot.
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The CUE Domain of gp78 Is Required for CFTRF508
Binding
To identify the structural basis of the different functions of
gp78 and HRD1 in the ERAD of CFTRF508, we generated
a set of chimeric proteins, each of which contained the
N-terminal multiple transmembrane region, the central
region containing the RING finger domain, and the C-
terminal region of either gp78 or HRD1 (Figure 2A). First,
we examined the binding of each chimera to CFTRF508-
GFP. The two chimeras that contained the central region of
gp78, GGH-Myc and HGG-Myc, coimmunoprecipitated
with CFTRF508-GFP (Figure 2B, left), whereas the two
chimeras that contained the central region of HRD1, GHH-
Myc and HHG-Myc, did not. These results indicated that the
binding of gp78 to CFTRF508 is mediated by its central
region. Similar binding was also observed for Rfm chimeric
proteins, which contained mutations in their RING finger
domains (data not shown).
We next examined the ability of the chimeric proteins to
induce polyubiquitylation of CFTRF508-GFP. Polyubiqui-
tylation of CFTRF508-GFP was enhanced by coexpression
of GGH-Myc and HGG-Myc (Figure 2C, lanes 2 and 8), and
it was reduced by coexpression of the corresponding Rfm
chimeras by dominant-negative effect (lanes 3 and 9). Nei-
ther wild-type nor Rfm chimeras that contained the central
region of HRD1 had any effect on polyubiquitylation. These
results indicated that the binding of the central region of
gp78 to CFTRF508-GFP strongly correlates with specific
polyubiquitylation of CFTRF508-GFP.
We also investigated the effect of the chimeric proteins
on the degradation of CFTRF508-GFP by using a pulse-
chase experiment. Coexpression of Rfm chimeras contain-
ing the central region of gp78 delayed the degradation of
CFTRF508-GFP, whereas chimeras containing the central
region of HRD1 did not (Figure 2, D and E). These results
suggested that the central region of gp78 is responsible for
specific recognition of CFTRF508, and subsequent ubiqui-
tylation and degradation.
The most apparent difference between the central regions
of gp78 and HRD1 is the presence of a CUE domain in gp78.
We generated a CUE domain-deletion mutant of gp78-Myc
(gp78CUE-Myc) and a CUE domain-insertional mutant of
HRD1-Myc (HRD1CUE-Myc), and we expressed these
proteins in cells. Coimmunoprecipitation experiments dem-
onstrated that deletion of the CUE domain of gp78 resulted
in loss of affinity for CFTRF508-GFP and that insertion of
the CUE domain into HRD1 conferred CFTRF508-GFP
binding activity to HRD1 (Figure 3A). These results indi-
cated that the CUE domain of gp78 is both necessary and
sufficient for its association with CFTRF508.
The importance of the CUE domain in the polyubiquity-
lation of CFTRF508 was next examined. As shown in Fig-
ure 3B, coexpression of gp78CUE-Myc had no apparent
effect on polyubiquitylation. This result was consistent with
the loss of affinity of gp78CUE for CFTRF508-GFP. Con-
versely, an insertion of the CUE domain into HRD1 con-
ferred the ubiquitylating activity for CFTRF508 on HRD1
(Figure 3C). This was also consistent with the result that
HRD1CUE acquired the affinity for CFTRF508-GFP (Fig-
ure 3A). Together, these results indicated that the CUE do-
main of gp78 is prerequisite and sufficient for CFTRF508
recognition and subsequent ubiquitylation.
The association of gp78 with CFTRF508 was mediated
by its intrinsic CUE domain, which also has ubiquitin bind-
ing activity (Supplemental Figure 4; Zhong et al., 2004; Chen
et al., 2006). To determine whether the ubiquitin binding
region of the CUE domain overlapped the CFTRF508 bind-
ing region, we generated a gp78 mutant in which the ubiq-
uitin binding site in the CUE domain, MFP (amino acids
463-465), was mutated to AAR. The association of this mu-
tant (Cm gp78-Myc) with CFTRF508-GFP was nearly un-
detectable (Figure 3D), and the ubiquitylation activity of Cm
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Figure 2. The central region of gp78 is impor-
tant for the ERAD of CFTRF508. (A) Sche-
matic representation of chimeric gp78 and
HRD1 proteins. The multiple-transmembrane
region, RING finger domain, E2 binding re-
gion, and p97 binding region are indicated as
TM, Rf, E2, and p97, respectively. Hatched and
gray regions show gp78 and HRD1 sequences,
respectively. (B) Chimeras containing the cen-
tral region of gp78 physically associate with
CFTRF508. HEK293 cells transiently express-
ing CFTRF508-GFP and the indicated chi-
meric proteins were labeled for 1 h with
[35S]methionine, and cell lysates were sub-
jected to immunoprecipitation using anti-GFP
antibody (left) or anti-Myc antibody (right).
Twofold more cell lysate was used for immuno-
precipitation with anti-GFP antibody. Immune
complexes were analyzed by SDS-PAGE fol-
lowed by autoradiogram. (C) Chimeras contain-
ing the central region of gp78 promote ubiquity-
lation of CFTRF508. Expression vectors for
CFTRF508-GFP and HA-ubiquitin were trans-
fected into HEK293 cells, together with expres-
sion vectors for the indicated chimeric proteins.
Ubiquitylated CFTRF508-GFP was detected
by immunoprecipitation with anti-GFP anti-
body followed by immunoblot using anti-HA antibody. (D) Rfm chimeras containing the central region pf gp78 delay the degradation of
CFTRF508. HEK293 cells were pulse-labeled for 30 min with [35S]methionine, and chased for the indicated periods, and then CFTRF508-
GFP was immunoprecipitated and processed for autoradiography. (E) The radioactivity of CFTRF508-GFP at each time point in (D) was
normalized to the value at chase period 0 h. The data represents the averages and SD of three independent experiments.
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gp78 for CFTRF508-GFP was also abolished (Figure 3E).
These results indicated that the ubiquitin binding site of
gp78 is also the site of association of gp78 with CFTRF508.
Gp78 Has E4-like Ubiquitin Ligase Activity
Through its intrinsic CUE domain, gp78 associated with
both ubiquitin and CFTRF508. We were interested in
whether gp78 recognized ubiquitin that was already at-
tached to CFTRF508, and we catalyzed further ubiquityla-
tion in a manner similar to that of the so-called E4 enzymes.
We examined the in vitro ubiquitin ligase activity of gp78
toward GST alone, or an N-terminal ub-GST, which mimics
monoubiquitylated GST. For in vitro ubiquitylation analysis,
we used gp78, gp78CUE, HRD1, and HRD1CUE en-
zymes, which were overexpressed in HEK293 cells and im-
munopurified with anti-Myc antibody as described in Mate-
rials and Methods. gp78 ubiquitylated ub-GST, but not GST
alone, after 2-h incubation at 37°C, which indicated that
gp78 selectively ubiquitylates an already ubiquitin-conju-
gated substrate (Figure 4A, lanes 9 and 10). Notably, the
CUE domain deletion mutant of gp78 had very low ubiquity-
lation activity toward GST and ub-GST (Figure 4A, lanes 11
and 12). We also observed that gp78 preferentially binds to
oligoubiquitin rather than ubiquitin monomers (Supplemental
Figure 4). These results indicated that gp78 possesses an E4-like
ubiquitin ligase activity in vitro. As HRD1 inserted with the
CUE domain acquired gp78-like CFTRF508-associating
and -ubiquitylating activity in vivo, we tested whether
HRD1CUE acquired an E4-like ubiquitin ligase activity in
vitro. As shown in Figure 4B, HRD1CUE specifically ubiq-
Figure 3. The CUE domain of gp78 is essential for recognition of CFTRF508. (A) HRD1CUE but not gp78CUE physically associates with
CFTRF508. HEK293 cells expressing CFTRF508-GFP with or without (control lane) gp78-Myc, GXG-Myc, gp78CUE-Myc, HRD1-Myc, or
HRD1CUE-Myc were labeled for 1 h with [35S]methionine, and cell lysates were subjected to immunoprecipitation using anti-GFP antibody
(top) or anti-Myc antibody (bottom). Twofold more cell lysate was used for immunoprecipitation with anti-GFP antibody. Immune complexes
were analyzed by autoradiogram. (B) Gp78CUE does not affect CFTRF508 ubiquitylation. Expression vectors for CFTRF508-GFP and
HA-ubiquitin were transfected into HEK293 cells together with expression vectors for the indicated variants of gp78. Ubiquitylated
CFTRF508-GFP was detected by immunoprecipitation with anti-GFP antibody followed by immunoblot using anti-HA antibody.
(C) HRD1CUE acquired CFTRF508-GFP-ubiquitylating activity. Expression vectors for CFTRF508-GFP and HA-ubiquitin were trans-
fected into HEK293 cells together with expression vectors for the indicated variants of HRD1. Ubiquitylated CFTRF508-GFP was detected
by immunoprecipitation with anti-GFP antibody followed by immunoblot using anti-HA antibody. (D) Point mutations in the CUE domain
of gp78 (Cm gp78-Myc) nearly abolish its association with CFTRF508. HEK293 cells expressing CFTRF508-GFP, together with gp78-Myc
or Cm gp78-Myc, were lysed and subjected to immunoprecipitation using anti-GFP antibody, and immune complexes were analyzed by
immunoblot using anti-Myc antibody. (E) Cm gp78-Myc does not have CFTRF508 ubiquitylation activity. Expression vectors for
CFTRF508-GFP and HA-ubiquitin were transfected into HEK293 cells together with expression vectors for gp78-Myc or Cm gp78-Myc.






























































































































Figure 4. Gp78 and CUE domain inserted
HRD1 have an E4-like ubiquitin ligase activity in
vitro. (A) Gp78 has an E4-like ubiquitin ligase
activity in vitro. GST or ub-GST was incubated
with ubiquitin, E1, E2 (Ube2g2), and ubiquitin
ligase (wild-type gp78 or gp78CUE), as indi-
cated, and then it was analyzed by immunoblot
using anti-GST antibody. (B) HRD1CUE has
an E4-like ubiquitin ligase activity in vitro. GST
or ub-GST was incubated with ubiquitin, E1, E2
(Ube2g2), and ubiquitin ligase (wild-type gp78,
gp78CUE, wild-type HRD1, and HRD1CUE),
and then it was analyzed by immunoblot using
anti-GST antibody. *, nonspecific contamination in
the E3 immunoprecipitates; **, nonspecific monou-
biquitylated ub-GST by Ube2g2; and ***, unidenti-
fied signal.
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uitylated ub-GST, indicating the CUE domain conferred
the E4-like activity on HRD1. Again, HRD1CUE did not
ubiquitylate the GST, as was shown for gp78 (Figure 4B,
lanes 3 and 7). Although we could not rule out the effect
of proteins that coimmunoprecipitated with ubiquitin li-
gases, these results indicate that gp78 specifically ubiqui-
tylated ubiquitin-conjugated substrates in the CUE do-
main-dependent manner.
If gp78 serves as an E4-like enzyme for multiubiquitylation
of CFTRF508 in vivo, then some other E3 ubiquitin ligase
would have to mediate the initial ubiquitylation of intact
CFTRF508. It has been reported that the ubiquitin ligases
CHIP and RMA1 are involved in an early step of CFTR clear-
ance, before CFTR is dislocated from the ER (Meacham et al.,
2001; Younger et al., 2006). To examine whether CHIP or RMA1
served as an upstream E3 enzyme for the E4-like activity of
gp78, we generated CHIP and RMA1 knockdown cells by
using siRNA duplexes (Figure 5A). Although gp78 promoted
the ubiquitylation of CFTRF508 in CHIP knockdown cells, it
was unable to promote ubiquitylation in RMA1 knockdown
cells (Figure 5B), suggesting that RMA1 is specifically required
as an upstream E3 enzyme for the subsequent E4-like activity
of gp78. We tested this putative E3/E4 cooperation in in vitro
ubiquitylation assay by the incubation of GST or ub-GST
with RMA1 and gp78 (Supplemental Figure 5). No apparent
cooperative ubiquitylation for GST was observed, suggest-
ing that RMA1 had substrate specificity and did not exert its
E3 activity on GST. Ubiquitylation of CFTRF508 was also
impaired in gp78 knockdown cells, which confirmed the
importance of endogenous gp78 (Figure 5C). Knockdown of
gp78 also caused a delay in the degradation of CFTRF508,
and this delay was more pronounced when RMA1 was
knocked down (Figure 5, D and E). Simultaneous knock-
down of gp78 and RMA1 did not additively delay the deg-
radation of CFTRF508 (Figure 5, D and E). These data
suggested that RMA1 functions upstream of gp78. Knock-
down of CHIP also caused a delay in the degradation of
CFTRF508 (Figure 5, D and E), comparable with that
caused by gp78 knockdown. This result was confirmed with
other siRNA duplexes (Supplemental Figure 6). These re-
sults suggested that the degradation of CFTRF508 is me-
diated by at least two independent pathways—one pathway
mediated by CHIP, and one pathway mediated by RMA1-












































































































































Figure 5. RMA1 functions upstream of gp78. (A) Knockdown efficiency was examined by immunoblot analysis for CHIP, gp78, and RMA1,
48 h after siRNA duplexes were transfected into HEK293 cells. Two independent sequences were adopted for knockdown of each gene.
(B) RMA1 knockdown specifically inhibits gp78 activity. HEK293 cells were cotransfected with siRNA duplexes targeting CHIP or RMA1,
and expression vectors for CFTRF508-GFP, HA-ubiquitin, and gp78-Myc. CFTRF508-GFP was immunoprecipitated using anti-GFP
antibody, followed by immunoblot using anti-HA antibody. (C) Endogenous gp78 is involved in the ubiquitylation of CFTRF508. HEK293
cells were cotransfected with siRNA duplexes targeting gp78, and expression vectors for CFTRF508-GFP and HA-ubiquitin. The ubiqui-
tylation of CFTRF508-GFP was examined 48 h after transfection. (D) Knockdown of gp78, CHIP, and RMA1 delay the degradation of
CFTRF508. An expression vector for CFTRF508-GFP and siRNA duplexes were transfected into HEK293 cells. Cells were pulse-labeled for
30 min with [35S]methionine, and then they were chased for indicated periods of time. CFTRF508-GFP was immunoprecipitated and processed for
autoradiography. (E) The radioactivity of CFTRF508-GFP at each time point in D was normalized to the value at chase period 0 h.
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Previous work showed that RMA1 physically associates
and functionally cooperates with Derlin-1, a putative chan-
nel protein for protein retrotranslocation during ERAD
(Younger et al., 2006). We tested physical interaction of gp78
with Derlin and RMA1 by immunoprecipitation with spe-
cific antibodies. Gp78 associates with all members of mam-
malian Derlin family proteins, Derlin1, -2, and -3 (Figure
6A); and with RMA1 (Figure 6B). Together, RMA1 and gp78
could associate each other via Derlin(s) and may function
successively in Derlin-containing complexes to polyubiqui-
tylate CFTRF508 as E3- and E4-like enzymes, respectively
(Figure 6C).
DISCUSSION
Hrd1p has been implicated in the ERAD of exogenously
expressed human CFTR in yeast cells (Gnann et al., 2004). In
the current study, we examined whether the mammalian
orthologues of yeast Hrd1p also participated in the ERAD of
CFTR in mammalian cells. We demonstrated that gp78, one
of the two mammalian Hrd1p orthologues, is involved in the
ERAD of CFTRF508, the most common mutant form of
CFTR, in mammalian cells. Analysis of overexpression of
ectopic gp78 and knockdown of endogenous gp78 showed
that gp78 plays a role in the ERAD of CFTRF508 in HEK293
cells (Figure 5).
We also demonstrated that the CUE domain of gp78 is
functionally significant in the ERAD of CFTRF508. Pre-
vious studies have precisely mapped the specific sites of
interaction between conserved amino acid side chains of
the CUE domain and side chains of ubiquitin (Kang et al.,
2003; Prag et al., 2003). The amino acids identified in these
previous studies were conserved in the CUE domain of
gp78, which suggested that the association of gp78 with
CFTRF508 (Figure 3D) occurs through a ubiquitin moi-
ety. This mechanism of binding to substrates via an inter-
vening ubiquitin molecule is used by the so-called mul-
tiubiquitin chain elongation factor E4. E4 likely recognizes
a ubiquitin moiety already attached to a mono- or oli-
goubiquitylated substrate, and it catalyzes further ubiq-
uitin elongation (Koegl et al., 1999; Hoppe, 2005; Richly et
al., 2005).
Ufd2, originally identified E4, cannot elongate ubiquitin
chain to ub-protein A without Ufd4, a cooperative E3 (Koegl
et al., 1999). This would be different from the case of gp78
reported here, which can ubiquitylate ub-GST without co-
operative E3 in vitro. The precise enzymatic mechanism of
Ufd2 remains unclear. Recently, Tu et al. (2007) described the
crystal structure of full-length Ufd2, and they showed its
own E3 activity. Based on the crystal structure and func-
tional analysis, they proposed alternative models of how
Ufd2 (E4) and Ufd4 (E3) can cooperate to polyubiquitylate
substrate. The first model is a “sequential model” in which
substrate is first ubiquitylated by E3 followed by the elon-
gation of ubiquitin chain by E4. In this model, E4 can
catalyze the ubiquitylation reaction without E3. The other
model is a “cooperative model” in which E3 and E4
cooperatively catalyze the polyubiquitylation reaction. If
the enzymatic mechanism of E4-like activity of gp78 is
sequential, gp78 will ubiquitylate ub-GST without coop-
erative E3. Considering the in vitro ubiquitylation analy-
sis reported here, we propose that gp78 may sequentially
ubiquitylate CFTRF508 as an E4-like enzyme after the
initial ubiquitylation by E3.
It has been reported that various E4 enzymes require their
specific E3 enzymes (e.g., the E4 enzyme Ufd2 cooperates
with the E3 enzyme Ufd4 and the E4 enzyme p300 cooper-
ates with the E3 enzyme Mdm2) (Koegl et al., 1999; Gross-
man et al., 2003; Hoppe, 2005). In the current study, we
showed that RNA interference-mediated knockdown of
RMA1 strongly reduced gp78-mediated ubiquitylation of
CFTRF508, whereas knockdown of CHIP had no apparent
effect. Both RMA1 and CHIP have been reported to possess
E3 activity and to ubiquitylate CFTRF508. Our results in-
dicate that the E4-like enzyme gp78 sequentially cooperates
with RMA1 in the ubiquitylation of CFTRF508. In addi-
tion, the interaction between gp78 and RMA1 putatively
mediated via Derlin(s) suggest a direct transfer of
CFTRF508 from E3 to E4 in the same complex (Figure
6C). RMA1 seems to act cotranslationally and CHIP post-
translationally to select CFTR for ERAD (Younger et al.,
2006). It takes 10 min to synthesize CFTR; so, it is possible
that pools of CFTR that are initially ubiquitylated by
RMA1 may not be immediately retrotranslocated and de-
graded. Such stalled forms of ubiquitylated CFTR might
become substrates of deubiquitinating enzymes. There-
fore, the binding of polyubiquitylated CFTR by the CUE
domain of gp78 might ward off the effects of deubiquity-
lating enzymes and serve to maintain the length or extend
of ubiquitin chains attached to CFTR during the time gap
between its initial ubiquitylation and retrotranslocation
from the ER membrane. CHIP seems to act posttransla-
tionally, so the ubiquitin chains attached to CFTR would
be recognized immediately and there would be no need
for an E4 enzyme. However, we should point out that the
study was done with CFTRF508 transiently overex-
pressed in HEK293 cells; thus, the study still leaves open
the exact extent to which the E4-like activity of gp78 is
relevant to the physiological and clinical situation.
In vitro study shown in Figure 4 indicated that gp78
specifically ubiquitylated ubiquitin-fused GST, but not intact
Figure 6. Gp78 interacts with Derlins and RMA1. (A) Gp78 asso-
ciates with Delin proteins. HEK293 cells transiently expressing
gp78-Flag and the Myc-tagged Derlin family proteins were labeled
for 1 h with [35S]methionine, and cell lysates were subjected to
immunoprecipitation using anti-Flag antibody (top) or anti-Myc
antibody (bottom). Immune complexes were analyzed by SDS-
PAGE followed by autoradiogram. (B) Gp78 associates with RMA1.
HEK293 cells transiently expressing gp78-Myc and Flag-RMA1
were lysed and subjected to immunoprecipitation using anti-Myc
antibody, and immune complexes were analyzed by immunoblot
using anti-Flag antibody. (C) Model of sequential ubiquitylation of
CFTRF508 by RMA1 and gp78-containing complexes.
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GST. However, it is not clear which lysine residue(s) in
Ub-GST was ubiquitylated by gp78. E4 enzyme was origi-
nally defined as a ubiquitin ligase that elongates the ubiq-
uitin chain on the mono- or oligoubiquitins already attached
on the substrates. If gp78 catalyzed extensive ubiquitylation
on the ubiquitin moiety of Ub-GST, gp78 should be classi-
fied as the E4 enzyme; however, if gp78 ubiquitylated GST
moiety of Ub-GST, it will not be a typical E4 enzyme itself,
but is a specific class of ubiquitin ligase, which needs the
ubiquitin moiety on the substrate for its ligase activity. Al-
though we cannot conclude which is the case in the present
study, we can attribute this gp78 activity as “E4-like activ-
ity,” because it needs initial ubiquitylation by other ubiq-
uitin ligase in the ERAD of CFTRF508.
Previously, it was reported that mutations in the CUE
domain of gp78 that impaired its ability to undergo self-
ubiquitylation and to ubiquitylate the substrate CD3- did
not affect the physical association of gp78 with CD3- (Chen
et al., 2006). This observation suggests that a ubiquitin
moiety is not needed for the association of gp78 and
CD3- and that gp78 has a substrate recognition domain
for CD3- that is independent of the ubiquitin binding
domain. Thus, Gp78 may function as an E3 ubiquitin
ligase in the ERAD of CD3-, and as an E4-like enzyme in
the ERAD of CFTRF508.
Two models of substrate recognition by gp78 are possible.
In the first, gp78 directly recognizes a substrate through a
specific recognition domain, which is distinct from the CUE
domain. If a substrate has an affinity for this putative sub-
strate recognition domain of gp78, gp78 associates with the
intact substrate and catalyzes its ubiquitylation. Alterna-
tively, if a substrate does not have a high enough affinity for
the substrate recognition domain, gp78 cooperates with
RMA1 to polyubiquitylate the substrate. Another possibility
is that cofactors of gp78 influence the enzymatic activity of
gp78. Recently, it was proposed that several factors, includ-
ing HRD1, gp78, EDEM, Derlin, VIMP, p97/VCP, PNGase,
and proteasome constitute a functional complex, which dis-
patches substrates effectively for succeeding steps of ERAD,
including dislocation from the ER, ubiquitylation, deglyco-
sylation, and degradation (Lilley and Ploegh, 2004, 2005; Ye
et al., 2004, 2005; Li et al., 2006; Oda et al., 2006; Carvalho et
al., 2006). The enzymatic specificity of gp78 may be regu-
lated by the combination of ERAD factors present in gp78-
containing complexes. Thus, gp78 may function as an
E4-like enzyme when it is a component of RMA1-contain-
ing complexes. Likewise, RMA1 may catalyze oligoubiq-
uitylation when it is present in gp78-containing com-
plexes, and full ubiquitylation in complexes of a different
molecular composition. Future studies will address the
molecular determinants of gp78 enzymatic activity and the
different pathways of ERAD in mammalian cells.
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